FILING ANALYSIS · MONDAY, NOVEMBER 16
20/20 Biolabs, Inc. AIDX — 8-K: Results of Operations and Financial Condition
positive
20/20 BioLabs reported a 4.1% increase in OneTest revenue to $1.36 million for the first nine months of 2026, with a gross margin expansion to 32.8%, and announced a two-year contract with Vermont for firefighter cancer screening, expected to contribute revenue in Q4 2026. The company has $3.63 million in cash and no outstanding debt as of September 30, 2026.
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →